inclusion criteria: * healthy individuals aged 18-59 years as well as 60 years and above who can provide legal identification (males and females are both required). * willing to participate in the study with informed consent prior to screening * negative in sars-cov-2 igg and igm test at screening. * women of childbearing potential must be using effective method of birth control for 14 days prior to the enrollment of the study and must agree to continue such precautions during the study until 30 days after the second dose of the study vaccine/placebo. * male subjects must agree to employ acceptable contraception from the day of first dose of the study vaccine/placebo until 30 days after the second dose of the study vaccine/placebo.

inclusion criteria: * healthy individuals aged 18-59 years as well as 60 years and above who can provide legal identification (males and females are both required). * willing to participate in the study with informed consent prior to screening * negative in sars-cov-2 igg and igm test at screening. * women of childbearing potential must be using effective method of birth control for 14 days prior to the enrollment of the study and must agree to continue such precautions during the study until 30 days after the second dose of the study vaccine/placebo. * male subjects must agree to employ acceptable contraception from the day of first dose of the study vaccine/placebo until 30 days after the second dose of the study vaccine/placebo.

inclusion criteria: - healthy individuals aged 18-59 years as well as 60 years and above who can provide legal identification (males and females are both required). - willing to participate in the study with informed consent prior to screening - negative in sars-cov-2 igg and igm test at screening. - women of childbearing potential must be using effective method of birth control for 14 days prior to the enrollment of the study and must agree to continue such precautions during the study until 30 days after the second dose of the study vaccine/placebo. - male subjects must agree to employ acceptable contraception from the day of first dose of the study vaccine/placebo until 30 days after the second dose of the study vaccine/placebo.

inclusion criteria: - healthy individuals aged 18-59 years as well as 60 years and above who can provide legal identification (males and females are both required). - willing to participate in the study with informed consent prior to screening - negative in sars-cov-2 igg and igm test at screening. - women of childbearing potential must be using effective method of birth control for 14 days prior to the enrollment of the study and must agree to continue such precautions during the study until 30 days after the second dose of the study vaccine/placebo. - male subjects must agree to employ acceptable contraception from the day of first dose of the study vaccine/placebo until 30 days after the second dose of the study vaccine/placebo.